Company / Operating Cash Flow
OCULAR THERAPEUTIX, INC Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$204.9M
FY2025
5-year range
-$204.9M / -$53.6M
FY2021-FY2025
Trend
-52.1%
vs FY2024
Sector context
#171 of 216
Health Care
What the data says
OCULAR THERAPEUTIX, INC's operating cash flow of -$205M is lower than 79% of companies in the Health Care sector (FY2025). Operating Cash Flow has declined for 3 consecutive years, from -$54M in FY2022 to -$205M in FY2025.
Based on SEC 10-K filings.
-$205M in FY2025.
Declined from -$70M to -$205M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 216This company -$204.9M Sector average $659.0M
▼
-131.1% below sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 52.1% year-over-year.
- Ranks #171 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$204.9M | -52.1% |
| FY2024 | -$134.7M | -91.8% |
| FY2023 | -$70.2M | -31.1% |
| FY2022 | -$53.6M | +31.0% |
| FY2021 | -$77.6M | +0.0% |
| FY2020 | -$77.6M | -53.7% |
| FY2019 | -$50.5M | -2.5% |
| FY2018 | -$49.2M | +2.5% |
| FY2017 | -$50.5M | -48.4% |
| FY2016 | -$34.0M | -168.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026